Research on the drug resistance mechanisms of meropenem and ciprofloxacin in clinical isolates of Pseudomonas aeruginosa

doi:10.3969/j.issn.1673-8640.2014.06.016

Abstract

Abstract: Objective To investigate the drug resistance mechanisms of both meropenem and ciprofloxacin in clinical isolates of Pseudomonas aeruginosa. Methods A total of 30 isolates of Pseudomonas aeruginosa which had been tested resistance to both meropenem and ciprofloxacin by VITEK-2 Compact were collected. Agar dilution method was used to reexamine the minimal inhibitory concentrations (MIC) of meropenem and ciprofloxacin. Carbapenemases were detected by modified three-dimensional test. The resistance genes were analyzed by polymerase chain reaction (PCR) amplification. The expression of efflux systems was analyzed by reverse transcription PCR. Results The same results were showed between agar dilution method and VITEK-2 Compact. Carbapenemases were not detected by modified three-dimensional test. The overexpression ofmexX and mexC genes were detected by reverse transcription PCR. The sequencing of regulatory genes showed that there were 4 isolates which the Gly(GGC) of nfxB was substitute for Val(GTC) and 6 isolates which the Val(CTG)of mexZ was substitute for Gly (CAG). Conclusions The overexpression of the MexXY-OprM and MexCD-OprJ efflux system, due to the mutation of regulatory genes of efflux system, is contributed to the drug resistance to both meropenem and ciprofloxacin of Pseudomonas aeruginosa.

Key words: Pseudomonas aeruginosa, Drug resistance mechanism, Meropenem, Ciprofloxacin, Efflux system

CLC Number:

R446.5

ZHANG Guodong, WANG Ying, ZHU Hongsheng. Research on the drug resistance mechanisms of meropenem and ciprofloxacin in clinical isolates of Pseudomonas aeruginosa[J]. , 2014, 29(6): 646-650.

References

[1] Rodríguez-Martínez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa[J] . Antimicrob Agents Chemother, 2009,53(11):4783-4788.
[2] Pasca MR, Dalla Valle C, De Jesus Lopes Ribeiro AL,et al. Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates[J] . Microb Drug Resist, 2012,18(1):23-32.
[3] 邵海枫,刘金波,张小卫,等.用于三维试验的最适酶抑制剂浓度探讨[J] .临床检验杂志,2003,21(6):352-353.
[4] Coban AY, Ekinci B, Durupinar B. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates[J] . Chemotherapy, 2004, 50(1): 22-26.
[5] Valdezate S, Vindel A, Echeita A, et al. Topoisomerase Ⅱ and Ⅳ quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility[J] . Antimicrob Agents Chemother, 2002, 46(4): 665-671.
[6] Linares JF, López JA, Camafeita E,et al. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type Ⅲ secretion in Pseudomonas aeruginosa[J] . J Bacteriol,2005,187(4):1384-1391.
[7] Hammami S, Ghozzi R, Burghoffer B, et al. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital[J] . Pathol Biol (Paris),2009,57(7-8):530-535.
[8] Campo Esquisabel AB, Rodríguez MC, Campo-Sosa AO,et al .Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime[J] . Clin Microbiol Infect, 2011,17(12): 1817-1822.
[9] Higgins PG, Fluit AC, Milatovic D, et al. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa[J] . Int J Antimicrob Agents, 2003, 21(5): 409-413.
[10] 曾章锐,邵海枫,王卫萍,等. 头孢菌素敏感或中介的铜绿假单胞菌对亚胺培南耐药机制的研究[J] . 临床检验杂志,2013,31(1):24-27.
[11] Levine C, Hiasa H, Marians KJ. DNA gyrase and topoisomerase Ⅳ: biochemical activities, physiological roles during chromosome replication, and drug sensitivities[J] . Biochim Biophys Acta, 1998,1400(1-3):29-43.
[12] Hocquet D, Nordmann P, El Garch F,et al. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa[J] . Antimicrob Agents Chemother, 2006,50(4):1347-1351.
[13] Masuda N, Sakagawa E, Ohya S,et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa[J] . Antimicrob Agents Chemother, 2000,44(12):3322-3327.
[14] Kriengkauykiat J, Porter E, Lomovskaya O, et al. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa[J] . Antimicrob Agents Chemother, 2005, 49(2): 565-570.

[1]	FEI Bing, LIU Ying, REN Yanying, GUO Mengyu, LIU Xinwei, LIU Dongmei, LI Yongwei. Research progress of cyclic diguanylate on the regulation of Pseudomonas aeruginosa biofilm [J]. Laboratory Medicine, 2023, 38(2): 186-189.
[2]	CHEN Qing, XU Rong, SUN Jingyong. Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa from patients with bronchiectasis in Shanghai [J]. Laboratory Medicine, 2023, 38(11): 1020-1025.
[3]	ZHAI Shana, SUN Qinghai, YU Yongwu, YE Fang, LIU Maodong. Influence of vancomycin combined with meropenem on serum TNF-α,PCT,IL-6 and peritoneal fluid WBC count in PDRP patients [J]. Laboratory Medicine, 2022, 37(4): 360-364.
[4]	WANG Lixin, SU Yunfu, WANG Yi. Research progress on the drug resistance mechanism of clinical pathogens to fosfomycin [J]. Laboratory Medicine, 2022, 37(10): 993-997.
[5]	LI Chanchan, WANG Ru, LUO Wenying. Research progress of Pseudomonas aeruginosa transcription factor PsrA [J]. Laboratory Medicine, 2020, 35(8): 832-836.
[6]	ZHONG Feng, FENG Yi, ZHANG Jingjing, XU Yan, FANG Yongmei, TAO Xiubin, WU Jing. In vitro antimicrobial activity and biofilm inhibitory effect of imipenem combined with tigecycline against mucoid Pseudomonas aeruginosa [J]. Laboratory Medicine, 2020, 35(6): 519-523.
[7]	ZHANG Xinyu, DU Xuefei, ZOU Guiling, JIANG Xiaofeng. Research progress of tigecycline resistance mechanism for Acinetobacter baumannii [J]. Laboratory Medicine, 2019, 34(7): 656-660.
[8]	LI Wei, AI Fuqi, MA Yimin, WANG Bei, TIAN Yueru. Drug resistance mechanism of carbapenem resistant Providencia rettgeri carrying bla_NDM-1 [J]. Laboratory Medicine, 2019, 34(1): 67-70.
[9]	FAN Xuemei. Efficiency of azithromycin and tobramycin drug combination on Pseudomonas aeruginosa [J]. Laboratory Medicine, 2017, 32(10): 879-882.
[10]	ZHAO Hu. Drug resistance of invasive fungi and its mechanisms [J]. Laboratory Medicine, 2016, 31(9): 735-738.
[11]	HUANG Qiulan, FAN Deping, GAO Shouxia, LIU Hongchou, XUE Nali, NI Yuxing. Class Ⅰ integron for diagnosing imipenem resistance of Pseudomonas aeruginosa：a Meta-analysis [J]. Laboratory Medicine, 2016, 31(6): 491-498.
[12]	XU Weihong, XU Bin, YAO Yiting, HUANG Mingmin, ZHANG Jun, ZHAO Hu. Analysis of AmpC beta-lactamase and outer membrane porin OprD₂ gene deletion in Pseudomonas aeruginosa [J]. Laboratory Medicine, 2016, 31(4): 309-313.
[13]	SHU Wen, QIAN Ying, LIU Qingzhong. Drug resistance of Pseudomonas aeruginosa in a teaching hospital from 2010 to 2014 [J]. Laboratory Medicine, 2016, 31(12): 1055-1060.
[14]	YAN Wenjuan, LI Yi, WANG Shanmei, SUN Mingjie. Research on the drug resistance mechanism of carbapenem-resistant Escherichia coli [J]. Laboratory Medicine, 2016, 31(1): 56-60.
[15]	PENG Jinghong, HOU Yanqiang, XIE Duoshuang, LIU Jun, ZHENG Rong. Studies of 16S rRNA methylase gene and aminoglycoside modifying enzyme gene in Pseudomonas aeruginosa [J]. Laboratory Medicine, 2015, 30(6): 613-616.